Avarieux
back to explore
AN2 Therapeutics Inc logo

ANTX

AN2 Therapeutics Inc
NASDAQ NMS - GLOBAL MARKET· Pharmaceuticals· US· IPO 2022-03-25
$5.95
+0.00 (+0.00%)
last quote
Want the full multi-source brief on ANTX?
The agent pulls regulatory filings, news flow, prediction-market pricing, and macro context — then synthesizes what's not yet in the price.
open in agent
Today
Open
$5.95
High
$6.12
Low
$5.79
Previous close
$5.95
Fundamentals
Market cap
$225.66M
P/E (TTM)
—
P/S (TTM)
—
P/B
0.59x
Gross margin
—
Operating margin
—
Net margin
—
Rev growth (YoY)
—
EPS growth (YoY)
—
ROE
-52.35%
52W high
$7.19
52W low
$1.00
Beta
-1.01x
Industry peers
by market cap
ELTP-6.41%NMRA-2.17%SIGA+0.62%DERM+1.67%ORMP-2.76%LENZ+0.52%PLTH.CNGRIN.CN
Upcoming earnings
next 30 days
2026-11-10in 67 days
Q3 2026EPS est $-0.20
Recent SEC filings
CIK 1880438filing-language history →
42026-09-02reports 2026-09-01
4 KB
32026-08-27reports 2026-08-24
3 KB
42026-08-19reports 2026-08-17
8 KB
1442026-08-17
6 KB
42026-08-14
5 KB
10-Q2026-08-11reports 2026-06-30
9,048 KB
Recent news
2026-08-27 → 2026-09-03
Benzinga · 3d
AN2 Therapeutics To Reveal Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera At The SOHO 2026 Annual Meeting
AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced
SEC EDGAR Yahoo Finance TradingView Company website
This is the free preview

The agent layer adds regulatory-language drift detection, cross-venue prediction-market signals, macro overlays, programmable alert rules, overnight briefs, and a grounding verifier on every claim. 7-day Pro trial, no card required.

Start the trial